该行续指，公司在自免单抗管线上有丰富的产品布局，其中，QX001S(IL-23p40)是国内首个获批的乌司 奴单抗生物类似药，可显著提高银屑病治疗的临床可及性；QX008N(TSLP)完成慢性阻塞性肺疾病II期 入组，进度位于国产首位；QX005N(IL-4Rα)获突破性疗法认定，完成结节性痒疹III期入组； QX002N(IL-17A)完成强直性脊柱炎III期试验，预计2025H2提交BLA；QX004N(IL-23p19)治疗银屑病疗 效显著且安全，启动III期试验；QX013N是中国首款c-kit靶向生物药，完成慢性自发性荨麻疹Ia期试 验。 荃信生物-B(02509)午前涨超6%，截至发稿，涨6.45%，报29.04港元，成交额1528.28万港元。 天风证券（601162）发布研报指出，2024年中国自身免疫性疾病药物市场规模达363亿元，生物制剂占 比逐年提升，预计2030年提升至65.6%，其中：中国银屑病市场规模2030年预计达306.5亿元；2022年中 国强直性脊柱炎患者人数为390万人，预计到2030年市场规模达约463亿元。目前，银屑病与强直性脊柱 炎等自身免疫性疾病的一线治疗以糖皮质 ...

智通财经APP获悉，荃信生物-B(02509)午前涨超6%，截至发稿，涨6.45%，报29.04港元，成交额 1528.28万港元。 天风证券发布研报指出，2024年中国自身免疫性疾病药物市场规模达363亿元，生物制剂占比逐年提 升，预计2030年提升至65.6%，其中：中国银屑病市场规模2030年预计达306.5亿元；2022年中国强直性 脊柱炎患者人数为390万人，预计到2030年市场规模达约463亿元。目前，银屑病与强直性脊柱炎等自身 免疫性疾病的一线治疗以糖皮质激素、免疫抑制剂和非甾体抗炎药为主，存在疗程持续性较短与全身性 副作用等问题。 该行续指，公司在自免单抗管线上有丰富的产品布局，其中，QX001S(IL-23p40)是国内首个获批的乌司 奴单抗生物类似药，可显著提高银屑病治疗的临床可及性；QX008N(TSLP)完成慢性阻塞性肺疾病II期 入组，进度位于国产首位；QX005N(IL-4Rα)获突破性疗法认定，完成结节性痒疹III期入组； QX002N(IL-17A)完成强直性脊柱炎III期试验，预计2025H2提交BLA；QX004N(IL-23p19)治疗银屑病疗 效显著且安全，启动III期 ...

Core Viewpoint - Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan Securities (Hong Kong) as the sole sponsor [1] Company Overview - Tianchen Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of innovative drugs targeting allergic and autoimmune diseases, with a comprehensive pipeline of biological products across various medical fields [3] - The company has established two proprietary research and development platforms: a high-affinity antibody discovery platform and a bifunctional antibody development platform [3] Market Potential - The global autoimmune disease drug market is projected to grow from $138.9 billion in 2024 to $176.7 billion by 2030, with a compound annual growth rate (CAGR) of 4.1% [3] - The Chinese autoimmune disease drug market is expected to increase from $5.1 billion in 2024 to $19 billion by 2030, with a CAGR of 24.5% [3] - The global allergy disease drug market is anticipated to grow from $42.8 billion in 2018 to $68.8 billion in 2024, with a CAGR of 8.2%, reaching $111.4 billion by 2030 [3] Key Products - The core product, LP-003, is a next-generation anti-IgE antibody designed to treat allergic diseases, with the fastest clinical development progress among global candidates [4] - The key product, LP-005, is a bifunctional antibody fusion protein targeting C5 and C3b complement, aimed at treating various complement-mediated diseases [4] Clinical Development - LP-003 has received IND approval in China for multiple indications, including allergic rhinitis (AR) and chronic spontaneous urticaria (CSU), with ongoing Phase III trials for seasonal AR [5] - LP-005 is currently undergoing a Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH) and plans to initiate trials for other complement-mediated kidney diseases [5] Financial Overview - Tianchen Biopharmaceuticals reported other income and revenue of approximately RMB 2.23 million, RMB 3.07 million, RMB 1.38 million, and RMB 0.88 million for the fiscal years 2023, 2024, and the first half of 2025, respectively [6] - The company incurred total losses of approximately RMB 95.78 million, RMB 137.32 million, RMB 58.93 million, and RMB 94.21 million during the same periods [6][7]